Check for updates

OPEN ACCESS

EDITED BY Faisal Syed, University of North Carolina at Chapel Hill, United States

REVIEWED BY

David Zweiker, Klinik Ottakring, Austria Donah Zachariah, University Hospitals of North Midlands NHS Trust, United Kingdom

*CORRESPONDENCE Mien-Cheng Chen Schenmien@ms76.hinet.net

RECEIVED 13 February 2023 ACCEPTED 18 April 2023 PUBLISHED 10 May 2023

CITATION

Lee W-C, Fang H-Y, Wu P-J, Chen H-C, Fang Y-N and Chen M-C (2023) Outcomes of catheter ablation vs. medical treatment for atrial fibrillation and heart failure: a meta-analysis. Front. Cardiovasc. Med. 10:1165011. doi: 10.3389/fcvm.2023.1165011

COPYRIGHT

© 2023 Lee, Fang, Wu, Chen, Fang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Outcomes of catheter ablation vs. medical treatment for atrial fibrillation and heart failure: a meta-analysis

Wei-Chieh Lee^{1,2}, Hsiu-Yu Fang³, Po-Jui Wu³, Huang-Chung Chen³, Yen-Nan Fang³ and Mien-Cheng Chen^{3*}

¹Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ²Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan, ³Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan, ⁴Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Background: The benefit of catheter ablation vs. medical treatment has been reported to be inconsistent in randomized controlled trials (RCTs) for patients with atrial fibrillation (AF) and heart failure (HF) due to different enrollment criteria. This meta-analysis aimed to decipher the differential outcomes stratified by different left ventricular ejection fractions (LVEFs) and AF types.

Methods: We searched PubMed, Embase, ProQuest, ScienceDirect, Cochrane Library, ClinicalKey, Web of Science, and ClinicalTrials.gov databases for RCTs comparing medical treatment and catheter ablation in patients with AF and HF published before March 31, 2023. Nine studies were included.

Results: When patients were stratified by LVEF, improved LVEF and 6-min walk distance, less AF recurrence, and lower all-cause mortality in favor of catheter ablation were observed in patients with LVEF \leq 50% but not in patients with LVEF \leq 35%, and short HF hospitalization was observed in patients with LVEF \leq 50% and LVEF \leq 35%. When patients were stratified by AF types, improved LVEF and 6-min walk distance, better HF questionnaire score, and short HF hospitalization in favor of catheter ablation were observed both in patients with nonparoxysmal AF and mixed AF (paroxysmal and persistent) and less AF recurrence and lower all-cause mortality in favor of catheter ablation were observed in only patients with mixed AF. **Conclusions:** This meta-analysis showed improved LVEF and 6-min walk distance, less AF recurrence, and lower all-cause mortality in favor of catheter ablation vs. medical treatment in AF patients with HF and LVEF of 36%–50%. Compared with medical treatment, catheter ablation improved LVEF and had better HF status in patients with nonparoxysmal AF and mixed AF; however, AF recurrence and all-cause mortality in favor of catheter ablation were observed in only HF patients with mixed AF.

KEYWORDS

atrial fibrillation, heart failure, left ventricular ejection fraction, medical treatment, catheter ablation

Introduction

The prevalence of atrial fibrillation (AF) and heart failure (HF) has increased globally (1). Advanced age and underlying structural heart disease are risk factors for AF and HF, which may develop sequentially or coincidentally (2). Patients with both conditions have worse outcomes and a higher risk of adverse clinical events (3, 4). Therefore, appropriate

management of AF and HF is important to reduce morbidity and mortality in patients with AF and HF. One randomized controlled study showed that catheter ablation had a low reported rate of restoring sinus rhythm and did not improve N-terminal pro-Btype natriuretic peptide, 6-min walk distance, or quality of life in patients with persistent AF and HF when compared with rate control (5). However, several randomized controlled studies showed significant benefits from catheter ablation vs. rate control in terms of objective exercise performance, clinical symptoms, neurohormonal status, left ventricular ejection fraction (LVEF), unplanned hospitalization, and mortality in patients with persistent AF and HF (6-8). One randomized controlled trial (RCT) reported that catheter ablation was associated with a significantly lower rate of all-cause mortality or hospitalization for worsening HF than rhythm and rate control therapy in patients with paroxysmal and persistent AF and HF, especially in patients with LVEF $\geq 25\%$ (9). One study reported that timely treatment of arrhythmia-mediated cardiomyopathy might minimize irreversible ventricular remodeling in patients with persistent AF and HF related to LV systolic dysfunction (LVEF $\leq 45\%$) (10). However, another RCT reported that catheter ablation did not improve LVEF compared with the best medical treatment in HF patients with persistent AF and LVEF $\leq 35\%$ (11). In the subgroup analysis of the CABANA study, catheter ablation produced clinically important improvements in survival, freedom from AF recurrence, and quality of life compared with drug therapy in patients with paroxysmal or persistent AF and clinically stable heart failure with a mean LVEF of 55% (12). However, another open-label study showed no difference in all-cause mortality or HF events between catheter ablation and rate control in patients with highburden paroxysmal AF or persistent AF and HF symptoms (13). Therefore, the benefit of catheter ablation vs. medical treatment has been reported to be inconsistent in patients with AF and HF regarding clinical symptoms and outcomes. The discrepancy in outcomes between catheter ablation and medical treatment in patients with AF and HF may be due to different inclusion criteria in terms of HF diagnostic criteria and LVEF and AF types. Therefore, this meta-analysis aimed to decipher the differential outcomes of catheter ablation vs. medical treatment in patients with AF and HF, stratified by different LVEFs, New York Heart Association (NYHA) class ≥ II, and different AF types.

Methods

Search strategies, trial selection, quality assessment, and data extraction

Two cardiologists (W-CL and H-YF) performed a systematic literature search of the PubMed, Embase, ProQuest, ScienceDirect, Cochrane Library, ClinicalKey, Web of Science, and ClinicalTrials.gov databases for articles published before March 31, 2023. The databases were searched for relevant studies without language restrictions using the key terms "atrial fibrillation," "heart failure," "catheter ablation," and "medical treatment." Disagreements were resolved by a third reviewer (P-JW). This study included different RCTs that compared the efficacies of catheter ablation and medical treatment in patients with AF and HF. The inclusion criteria were a human study with parallel design and comparison of the efficacy of catheter ablation and medical treatment in patients with AF and HF. The inclusion criteria with AF and HF. The exclusion criteria were case reports or series, animal studies, review articles, conference abstracts, unpublished data, and observational studies. We did not set language limitations to increase the number of eligible articles. **Supplementary Figure S1** illustrates the literature search and screening protocol.

Outcomes

The outcomes of interest in this study were the change in LVEF, 6-min walk distance, HF questionnaire score, change in brain natriuretic peptide (BNP), AF recurrence, HF hospitalization, and all-cause mortality.

Statistical analysis

The frequency of each evaluated outcome was extracted from each study, and the data were presented as cumulative rates. A random-effects model was employed to pool the individual odds ratio (OR), and all analyses were performed using Comprehensive Meta-Analysis software version 3 (Biostat, Englewood, NJ, United States). To assess the heterogeneity across trials, we used the chi-squared test (values of $p \le 0.10$ were considered significant) and I2 statistics to examine each outcome from low to high heterogeneity (25%–75%, respectively). Potential publication bias was assessed using Egger's test *via* funnel plots, and statistical significance was set at $p \le 0.10$. Statistical significance was set at p < 0.05 to compare the catheter ablation and medical treatment groups.

Results

Characteristics of included studies

The study selection process is illustrated in **Supplementary Figure S1**. Nine studies met our inclusion criteria. The study design, study period, participant characteristics, AF type, HF criteria, mean LVEF, and follow-up period are described in **Table 1**. A total of 2,074 participants (mean age, 65 ± 7.6 years; 70.9% men) were included. Most participants in these studies had nonparoxysmal AF (68%–100%). The enrollment criterion for HF trial patients in four studies was LVEF \leq 35% (5, 6, 9, 11). In another three studies, different LVEF values were used to enroll HF patients, including \leq 50% (7), \leq 40% (8), and \leq 45% (10). The remaining two studies did not declare the LVEF cutoff value for enrollment and used only a history of NYHA functional classification \geq II as the enrollment criteria (12, 13).

First author (year)— study name	Patients number (male %)	Age (years)	Study period	Nonparoxysmal AF (%)	Enrollment criteria for HF	Mean LVEF of the two groups	Follow-up	Reference number
MacDonald MR (2011)	41 (78)	63 ± 7	January 2007– July 2009	100	NYHA class \geq II and LVEF \leq 35%	19.6 ± 5.5% vs. 16.1 ± 7.1%	6 months	5
Jones DG (2013)	52 (87)	63 ± 9	April 2009– June 2012	100	NYHA class ≥ II and LVEF ≤ 35%	$25 \pm 7\%$ vs. 22 $\pm 8\%$	12 months	6
Hunter RJ (2014)—ARC AF	50 (96)	57 ± 11	N/A	92	NYHA class ≥ II and LVEF ≤ 50%	$34 \pm 12\%$ vs. $32 \pm 8\%$	12 months	7
Di Biase (2016)— CAMTAF	203 (74)	61±11	N/A	100	NYHA class II, III, LVEF ≤ 40%, and an implanted defibrillator	30 ± 8% vs. 29 ± 5%	24 months	8
Marrouche NF (2018)— CASTLE-AF	363 (86)	64 ± 4	January 2008– January 2016	68	NYHA class \geq II, LVEF \leq 35%, and an implanted defibrillator	31.5 ± 2.5% vs. 32.5 ± 3.3%	37.8 months	9
Prabhu S (2018) —CAMERA MRI	36 (N/A)	61 ± 11	N/A	100	$LVEF \le 45\%$	$36 \pm 8.2\%$ vs. $33 \pm 8.0\%$	6 months	10
Kuck KH (2021)—AMICA	140 (90)	65 ± 8	January 2008– June 2016	100	$LVEF \le 35\%$	$24.8 \pm 8.8\%$ vs. $27.8 \pm 9.5\%$	12 months	11
Packer DL CABANA subgroup (2021)	778 (55)	67 ± 3	November 2009–April 2016	68	NYHA class ≥ II	56 ± 3% vs. 55 ± 3%	60 months	12
Parkash R (2022)—RAFTAF	411 (74)	67 ± 8	December 2011–January 2018	93	NYHA class II, III and elevated NT-proBNP	40.3 ± 14.6% vs. 41.0 ± 14.9%	24 months	13

TABLE 1 Characteristics of the nine included studies.

HF, heart failure; AF, atrial fibrillation; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; N/A, not applicable; NT-proBNP; N-terminal pro-B-type natriuretic peptide.

Patient demographics

Table 2 describes the details of patients' demographics between the medical treatment and catheter ablation groups of the enrolled study patients. The mean age, sex, NYHA functional classification, prevalence of diabetes mellitus, hypertension, prior stroke, ischemic cardiomyopathy, implantable cardioverter defibrillator, cardiac resynchronization therapy placement, nonparoxysmal AF, AF duration, mean LVEF, and use of HF medications did not differ significantly between the medical treatment and catheter ablation groups.

Pooled results of changes in LVEF, 6-min walk distance, HF questionnaire score, BNP level, AF recurrence, HF hospitalization, and all-cause mortality

Pooled results from the random-effects model showed that catheter ablation for AF, compared with medical treatment, was associated with an increased LVEF from baseline [mean difference 6.22%; 95% confidence interval (CI), 3.59%–8.86%] with high heterogeneity (Cochran's *Q*, 294.657; *df*, 7; I^2 , 97.624%; p < 0.001) (Figure 1A). Egger's test revealed nonsignificant publication bias in the change in LVEF (t, 0.309; *df*, 6; p = 0.767). The funnel plot of the change in LVEF is shown in Supplementary Figure S2. Pooled results from the random-effects model showed that catheter ablation vs. medical treatment was associated with an increased 6-min walk distance from baseline (mean difference, 0.97 m; 95% CI, 0.27–1.67 m), with

TABLE 2 Patients' demographics.

	Medical treatment	Catheter ablation	<i>P</i> value
Number	1,041	1,033	
Age (years)	65 ± 7.4 (1,041)	65 ± 7.8 (1,033)	1.000
Male sex (%)	71.5 (731/1,023)	70.3 (714/1,015)	0.551
Diabetes mellitus (%)	29.2 (289/991)	27.4 (269/981)	0.375
Hypertension (%)	73.4 (745/1,015)	71.5 (720/1,007)	0.339
Nonparoxysmal AF (%)	79.1 (808/1,022)	81.8 (827/1,011)	0.125
ICM (%)	41.0 (214/522)	37.9 (203/535)	0.303
Coronary artery disease (%)	31.6 (293/927)	30.9 (285/921)	0.746
Prior stroke (%)	10.3 (84/818)	10.5 (85/811)	0.895
NYHA class≥III (%)	39.1 (204/522)	42.8 (229/535)	0.222
ICD and CRT (%)	57.2 (274/479)	57.1 (278/487)	0.975
LA dimension (mm)	48.2 ± 6.3 (548)	47.6 ± 6.4 (563)	0.116
LVEF (%)	41.7 ± 14.9 (1,041)	41.2 ± 14.1 (1,033)	0.433
CHA2DS2-VASc score	3.1 ± 1.2 (615)	3.1 ± 1.2 (610)	1.000
AF duration (months)	16.6 ± 21.3 (785)	15.7 ± 16.1 (786)	0.345
ACEI/ARB (%)	88.3 (545/617)	86.2 (542/629)	0.267
β-blocker (%)	84.4 (521/617)	82.7 (520/629)	0.419
MRA (%)	59.0 (364/617)	60.9 (383/629)	0.494

AF, atrial fibrillation; ICM, ischemic cardiomyopathy; NYHA, New York Heart Association; ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; LA, left atrium; LVEF, left ventricular ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; MRA, mineralocorticoid receptor antagonist.

Data are expressed as mean \pm SD or number (percentage).

high heterogeneity (Cochran's Q, 94.559; df, 5; I^2 , 94.712%; p < 0.001) (Figure 1B). Egger's test revealed a nonsignificant publication bias regarding the change in the 6-min walk distance (t, 0.782; df, 4; p = 0.478). The funnel plot for the change in the



Forest plots comparing the changes in LVEF, 6-min walk distance, HF questionnaire score, BNP level, odds ratio for AF recurrence, odds ratio for HF hospitalization, and odds ratio for all-cause mortality of medical treatment versus catheter ablation. (A) Change of LVEF in eight studies. (B) 6-min walk distance in six studies. (C) HF questionnaire in six studies. (D) Change of BNP level in six studies. (E) AF recurrence rate in five studies. (F) HF hospitalization rate in five studies. (G) All-cause mortality rate in five studies. AF, atrial fibrillation; BNP, B-type natriuretic peptide; HF, heart failure; LVEF, left ventricular ejection fraction.

6-min walk distance is shown in Supplementary Figure S3. Pooled results from the random-effects model showed that catheter ablation vs. medical therapy was associated with an improved HF questionnaire score from baseline (mean difference, 0.86; 95% CI, 0.35-1.37) with high heterogeneity (Cochran's Q, 55.150; df, 5; I^2 , 90.934%; p < 0.001) (Figure 1C). Egger's test showed a nonsignificant publication bias in the change in the HF questionnaire score (t, 0.028; df, 4; p = 0.979). The funnel plot for the change in HF questionnaire score is shown in Supplementary Figure S4. Pooled results from the randomeffects model showed that catheter ablation vs. medical treatment was associated with significant change in the BNP level from baseline (mean difference, 2.58 pg/ml, 95% CI, 0.97-4.20 pg/ml) with high heterogeneity (Cochran's Q, 233.478; df, 5; I², 97.858%; p < 0.001) (Figure 1D). Egger's test revealed a nonsignificant publication bias for the change in the BNP level (t, 0.392; df, 4; p = 0.715). The funnel plot for the change in the BNP level is shown in Supplementary Figure S5. The overall OR of the recurrence of AF of the catheter ablation group vs. medical treatment was 4.26 (95% CI, 1.34-13.55) in favor of catheter ablation (Figure 1E) with high heterogeneity (Cochran's Q, 112.389; df, 4; I², 96.441%; p < 0.001). Egger's test revealed nonsignificant publication bias regarding the overall OR of AF recurrence (t, 0.382; df, 3; p = 0.728). A funnel plot for the log OR of AF recurrence is shown in Supplementary Figure S6. The overall OR of the HF hospitalization of catheter ablation vs. medical treatment was 1.72 (95% CI, 1.22-2.42) in favor of catheter ablation (Figure 1F) with moderate heterogeneity (Cochran's Q, 7.991; df, 4; I^2 , 49.946%; p = 0.092). Egger's test revealed a nonsignificant publication bias regarding the overall OR of hospitalization for HF (t, 0.180; df, 3; p = 0.869). A funnel plot for the log OR of HF hospitalization is shown in Supplementary Figure S7. The overall OR of the incidence of all-cause mortality of catheter ablation vs. medical treatment was 1.65 (95% CI, 1.25-2.20) in favor of catheter ablation (Figure 1G) with low heterogeneity (Cochran's Q, 3.622; df, 4; I^2 , 0%; p = 0.460). Egger's test revealed a nonsignificant publication bias regarding the overall OR of all-cause mortality (t, 0.215; df, 3; p = 0.844). The funnel plot for the log OR of all-cause mortality is shown in Supplementary Figure S8.

Pooled results of change in LVEF, 6-min walk distance, HF questionnaire score, BNP level, AF recurrence, HF hospitalization, and all-cause mortality stratified by different LVEFs

A greater improvement in LVEF in favor of catheter ablation vs. medical treatment was observed in the population with LVEF \leq 50% (mean difference, 9.54%; 95% CI, 0.04%–19.04%) but not in the population with LVEF \leq 35% (Figure 2A). A longer 6-min walk distance in favor of catheter ablation vs. medical treatment was observed in the population with LVEF \leq 50% (mean difference, 0.40 m; 95% CI, 0.03–0.75 m), but not in the population with LVEF \leq 35% (Figure 2B). Interestingly, a greater

improvement in HF questionnaire scores in favor of catheter ablation vs. medical treatment was observed in the population with LVEF \leq 35% (mean difference, 0.51; 95% CI, 0.14–0.89) but not in the population with LVEF $\leq 50\%$ (Figure 2C). There was no significant difference in the change in the BNP level between catheter ablation and medical treatment in the population with LVEF ≤35% (mean difference, 2.29 pg/ml; 95% CI, -0.30 to 4.87 pg/ml) and in the population with LVEF $\leq 50\%$ (mean difference, 2.57 pg/ml; 95% CI, -2.34 to 7.48 pg/ml) (Figure 2D). The risk of recurrence of AF was significantly lower by catheter ablation compared with medical treatment in the population with LVEF ≤50% (OR, 4.51; 95% CI, 2.50-8.14) but not in the population with LVEF $\leq 35\%$ (Figure 2E). The overall OR values of HF hospitalization were 1.93 (95% CI, 1.29-2.88), in favor of catheter ablation vs. medical treatment in the population with LVEF ≤35%, and 2.95 (95% CI, 1.66-5.24), also in favor of catheter ablation vs. medical treatment in the population with LVEF ≤50% (Figure 2F). The incidence of allcause mortality was significantly lower by catheter ablation compared with medical treatment in the population with LVEF ≤50% (OR, 2.55; 95% CI, 1.05-6.17) but not in the population with LVEF $\leq 35\%$ (Figure 2G).

Pooled results of change in LVEF, 6-min walk distance, HF questionnaire score, BNP level, AF recurrence, HF hospitalization, and all-cause mortality stratified only by NYHA ≥II

A greater improvement in LVEF in favor of catheter ablation vs. medical treatment was observed in the population with HF history (mean difference, 6.30%; 95% CI, 6.07%-6.53%) (Figure 3A). A longer 6-min walk distance in favor of catheter ablation vs. medical treatment was observed in the population with HF history (mean difference, 1.85 m; 95% CI, 1.62-2.08 m) (Figure 3B). A greater improvement in HF questionnaire scores in favor of catheter ablation vs. medical treatment was observed in the population with HF history (mean difference, 1.24; 95% CI, 1.03–1.45) (Figure 3C). A significant difference in the change in the BNP level in favor of catheter ablation vs. medical treatment was observed in the population with HF history (mean difference, 3.62 pg/ml; 95% CI, 3.30-3.93 pg/ml) (Figure 3D). There was no significant difference in the recurrence of AF, HF hospitalization, and all-cause mortality between catheter ablation and medical treatment in the population with HF history of NYHA \geq II (Figures 3E–G).

Pooled results of change in LVEF, 6-min walk distance, HF questionnaire score, BNP level, AF recurrence, HF hospitalization, and all-cause mortality stratified by AF types

Mixed AF was defined as the study population with paroxysmal and persistent AF (14). A greater improvement in LVEF in favor of

	study name	Statistics	for each stu	udy			Difference in	means and 95% Cl		
Group by LVEF		Standard	Variance	Lower L	lpper limit					Relative
<0=0/	MacDonald MR (2011) 1.70	error 2.92	Variance 8.54	-4.03	7.43	1	1 -		I	weight 21.57
≤35%	Jones DG (2013) 5.50 Marrouche NF (2018) 7.80	2.80 0.47	7.87 0.22	0.00 6.87	11.00 8.73			┝╼┶	-	21.99 28.20
	Kuck KH (2021) 0.15	0.44	0.19	-0.70	1.00			ŧ⊺		28.20
< E 00/	3.82 Hunter RJ (2014) 14.50	2.76 1.32	7.63 1.73	-1.59 11.92	9.23 17.08				_	33.65
≤50%	Di Biase L (2016) 1.90 Prabhu S (2018) 12.50	0.64	0.40 5.23	0.65 8.02	3.15 16.98			➡ _	_	34.30 32.04
	9.54	4.85	23.49		19.04					
B. 6-min	ute walk distance					-15.00	-7.50	0.00 7.50	15.00	
		Statistics	or each stu	udv			Std diff i	eans and 95% Cl		
Group by LVEF		tandard			per		<u>att dir in in</u>			Relative
	in means MacDonald MR (2011) 0.02	error 0.31	Variance 0.10		mit 0.63		· -	<u> </u>		weight 32.35
≤35%	Jones DG (2013) 1.06	0.30	0.09	0.48	1.64			⊺_ ∔		32.77
	Kuck KH (2021) 1.75 0.96	0.20 0.51	0.04 0.26		2.14 1.97				·	34.87
≤50%	Di Biase L (2016) 0.31 Prabhu S (2018) 0.73	0.14	0.02		0.58 1.40			-		77.62 22.38
	Prabhu S (2018) 0.73 0.40	0.34 0.18	0.12 0.03		0.75					22.30
o o						-3.00	-1.50	0.00 1.50	3.00	
	estionnaire									
Group by LVEF		Statistics for the statistics for the state of the state	or each stu		par		Std diff in m	eans and 95% Cl		Polativa
	in means	error \	/ariance		nit					Relative weight
≤35%	MacDonald MR (2011) 0.15 Jones DG (2013) 0.93	0.31 0.29	0.10 0.09		0.77 1.51		· · ·	╊──────		25.08 27.53
	Kuck KH (2021) 0.46	0.17	0.03	0.12	0.80			⊕		47.39
<500/	0.51 Hunter RJ (2014) 2.29	0.19 0.36	0.04 0.13		0.89 3.00				-	48.61
≤50%	Di Biase L (2016) 0.28 1.25	0.14	0.02	0.00	0.55					51.39
	1.25	1.00	1.01	-0.71	3.22	-4.00	-2.00	0.00 2.00	4.00	
D. The cl	nange of BNP									
Group by			or each stu				Std diff in m	eans and 95% CI		
	Std diff S in means	andard error	Variance		oper mit					Relative weight
≤35%	MacDonald MR (2011) 0.24	0.31	0.10		0.86			╞ _┻ ╵	1	33.38
20070	Jones DG (2013) 1.90 Kuck KH (2021) 4.72	0.33 0.33	0.11 0.11	4.08	2.56 5.36					33.30 33.32
	2.29 Hunter RJ (2014) 0.10	1.32	1.74		4.87 0.66					50.78
≤50%	Prabhu S (2018) 5.12 2.57	0.69	0.47 6.28	3.77	6.47 7.48					49.22
	2.57	2.51	0.20	2.04		-8.00	-4.00	0.00 4.00	8.00	
E. The re	currence of AF									
Group by	Study name						Odds ratio a	nd 95% Cl		
LVEF			Lower	Upper						Relative
		ratio	limit	limit	,			- 1		weight
≤35%	Marrouche NF (2018) Kuck KH (2021)	6.16 0.51	3.88 0.25	9.80 1.04				-=1		50.64 49.36
	1.00K (XI (2021)	1.79	0.25							-0.00
≤50%	Di Biase L (2016)	4.51	2.50	8.14	- 1		1 T	-		100.00
		4.51	2.50	8.14	1		1		I	
					0.0	1	0.1 1	10	100	
F. HF hos	spitalization									
Group by	Study name						Odds ratio a	nd 95% CI		
LVEF		Odds	Lower	Upper			a			Relative
		ratio	limit	limit						weight
≤35%	Marrouche NF (2018)	2.15	1.34	3.44	1	1	1 1	- H - I		72.59
200/0	Kuck KH (2021)	1.45	0.68	3.13			-+	- <u>∔</u>		27.41
~= ~ ~ /	Di Bioso L (2018)	1.93	1.29	2.88						100.00
≤50%	Di Biase L (2016)	2.95 2.95	1.66 1.66	5.24 5.24						100.00
		2.00			0.1	0.2	0.5 1	2 5	10	
G. The in	cidence of all-cause n	nortal	itv		0.1	0.2		- 5		
		ioital	y					105% 61		
Group by LVEF	Study name	_					Odds ratio a	ind 95% Cl		
		Odds ratio	Lower limit	Upper limit						Relative weight
<2F0/	Marrouche NF (2018		1.25		Т	Т	1 1	 I	1	64.85
≤35%	Kuck KH (2021)	0.94	0.33							04.05 35.15
		1.61	0.74	3.50			-			
5							· · ·			100.00
≤50%	Di Biase L (2016)	2.55 2.55	1.05 1.05		I					100.00

Forest plots comparing the changes in LVEF, 6-min walk distance, HF questionnaire score, BNP level, odds ratio for AF recurrence, odds ratio for HF hospitalization, and odds ratio for all-cause mortality of medical treatment versus catheter ablation in patients stratified by LVEF (LVEF \leq 35% and LVEF \leq 50%). (A) Change in LVEF in seven studies (\leq 35% in four, \leq 50% in three). (B) 6-min walk distance in five studies (LVEF \leq 35% in three, LVEF \leq 50% in two). (C) HF questionnaire score in five studies (LVEF \leq 35% in three, LVEF \leq 50% in two). (C) HF questionnaire score in three studies (LVEF \leq 35% in three, LVEF \leq 50% in one). (B) AF recurrence in three studies (LVEF \leq 35% in two, LVEF \leq 50% in one). (F) HF hospitalization in three studies (LVEF \leq 35% in two, LVEF \leq 50% in one). (G) All-cause mortality rate in three studies (LVEF \leq 35% in two, LVEF \leq 50% in one). AF, atrial fibrillation; BNP, B-type natriuretic peptide; HF, heart failure; LVEF, left ventricular ejection fraction.



hospitalization, and odds ratio for all-cause mortality of medical treatment versus catheter ablation in patients stratified by NYHA≥II without LVEF. (A) Change in LVEF in one study. (B) 6-min walk distance in one study. (C) HF questionnaire score in one study. (D) BNP level in one study. (E) AF recurrence in two studies. (F) HF hospitalization in two studies. (G) All-cause mortality rate in two studies. AF, atrial fibrillation; BNP, B-type natriuretic peptide: HF, heart failure: LVEF, left ventricular ejection fraction.

catheter ablation vs. medical treatment was observed in the population with nonparoxysmal AF (mean difference, 3.68%; 95% CI, 0.82%-6.54%) and mixed AF (mean difference, 9.07%; 95% CI, 6.46%-11.69%) (Figure 4A). A longer 6-min walk distance in favor of catheter ablation vs. medical treatment was observed in the population with nonparoxysmal AF (mean difference, 0.78 m; 95% CI, 0.11-1.45 m) and mixed AF (mean difference, 1.85 m; 95% CI, 1.62-2.08 m) (Figure 4B). A greater

Group by AF type	Study name		Statistics f		and design of the			Difference	ce in means and 95	% CI			
		in means	Standard error	Variance	limit	limit						Relative weight	
	MacDonald MR (2011) Jones DG (2013)	1.70 5.50	2.92	8.54 7.87	-4.03 0.00	7.43 11.00		-				13.40 14.00	
Non-paroxysmal	Di Biase L (2016)	1.90	0.64	0.40	0.65	3.15				-		27.45	
	Prabhu S (2018) Kuck KH (2021)	12.50 0.15	2.29	5.23 0.19	8.02	16.98			+			16.92 28.23	
2 551 57 5	Hunter RJ (2014)	3.68 14.50	1.46 1.32	2.13 1.73	0.82	6.54 17.08			-	-		27.32	
Mixed	Marrouche NF (2018)	7.80	0.47	0.22	6.87	8.73				_# -		35.56	
	Parkash R (2022)	6.30 9.07	0.12	0.01 1.78	6.07 6.46	6.53 11.69				-		37.12	
B. 6-minute	walk distand	e					-15.00	-7.50	0.00	7.50	15.00		
Group by	Study name		Statistics	for each s	tudy			Std diff	in means and 95	% CI			
AF type		Std diff	Standard		Lower	Upper						Relative	
	MacDonald MR (2011)	in means 0.02	error 0.31	Variance 0.10	limit -0.60	limit 0.63	T.		_	T.	1	weight 19.10	
Non-paroxysmal	Jones DG (2013)	1.06	0.30	0.09	0.48	1.64			-	•		19.43	
	Di Biase L (2016) Prabhu S (2018)	0.31 0.73	0.14	0.02	0.03	0.58				_		21.87 18.49	
	Kuck KH (2021)	1.75	0.20	0.04	1.36 0.11	2.14 1.45			-	_ 		21.11	
Mixed	Parkash R (2022)	1.85	0.12	0.01	1.62	2.08				-		100.00	
		1.85	0.12	0.01	1.62	2.08	-3.00	-1.50	0.00	1.50	3.00		
C. HF Ques	tionnaire						-0.00	-1.50	0.00	1.50	0.00		
			-										
Group by AF type	Study name	Std diff	Statistics Standard	for each s	Lower	Upper		Std diff	in means and 95	% CI		Relative	
		in means	error	Variance	limit	limit						weight	
Non-paroxysmal	MacDonald MR (2011) Jones DG (2013)	0.15	0.31 0.29	0.10	-0.46 0.36	0.77	1		+	- 1	1	14.22 15.88	
	Di Biase L (2016)	0.28	0.14	0.02	0.00	0.55			-			38.17	
	Kuck KH (2021)	0.46 0.42	0.17	0.03	0.16	0.80 0.68			•			31.73	
Mixed	Hunter RJ (2014) Parkash R (2022)	2.29 1.24	0.36	0.13	1.57	3.00 1.45				. † ∎−'		44.50 55.50	
	. 5.1401.14 (2022)	1.70	0.52	0.27	0.68	2.72	1				1		
							-4.00	-2.00	0.00	2.00	4.00		
D. The char	nge of BNP												
Group by AF type	Study name			for each st	tudy			Std diff	in means and 95	% CI			
Al type		Std diff in means	Standard error	Variance	Lower	Upper limit						Relative weight	
	MacDonald MR (2011)	0.24	0.31	0.10	-0.37	0.86	1	- T	÷	1	1	25.45	
Non-paroxysmal	Jones DG (2013) Prabhu S (2018)	1.90 5.12	0.33	0.11	1.25	2.56 6.47				- -	e.	25.39 23.76	
	Kuck KH (2021)	4.72	0.33	0.11	4.08	5.36 5.24				-		25.40	
	Hunter RJ (2014)	0.10	1.16 0.28	0.08	-0.45	0.66			+			49.78	
Mixed	Parkash R (2022)	3.62	0.16	0.03	3.30	3.93 5.31			-			50.22	
							-8.00	-4.00	0.00	4.00	8.00		
E. The recu	rrence of AF												
Group by	Study name							Odds	ratio and 95% C	2			
AF type						pper						Relative	
	Di Rigge L (2016)					imit 8.14	T	1	1.4	-1	i.	weight 50.47	
Non-paroxysmal	Di Biase L (2016) Kuck KH (2021))				1.04		-				49.53	
						3.03		-					
Mixed	Marrouche NF (20 Packer DL CABA		up (2021)			9.80 3.13			#			33.29 33.90	
	Parkash R (2022)			40.61 2	3.05 7	1.56				-	⊢	32.81	
				8.25	1.74 3	9.19	0.01	0.1	1	10	100		
F. HF hospi	talization						0.01	0.1			.00		
Group by	Study name							Odds	ratio and 95% C	1			
				Odds Lo		oper						Relative	
AF type				ratio li	mit li	mit			a			weight	
	DID				1.66	5.24	1		_ ↓ ∎∓	-	1	56.67 43.33	
	Di Biase L (2016) Kuck KH (2021)			1.45	0.68	3.13							
AF type Non-paroxysmal	Kuck KH (2021)			2.17	1.09	4.32			-				
Non-paroxysmal	Kuck KH (2021) Marrouche NF (20)18)	up (2021)	2.17 2.15	1.09 1.34	4.32 3.44						33.97	
Non-paroxysmal	Kuck KH (2021))18) VA subgrou	ıp (2021)	2.17 2.15 1.10 1.49	1.09 1.34 0.67 0.92	4.32 3.44 1.79 2.41			╞╡				
Non-paroxysmal	Kuck KH (2021) Marrouche NF (20 Packer DL CABAt)18) VA subgrou	ıp (2021)	2.17 2.15 1.10 1.49	1.09 1.34 0.67 0.92	4.32 3.44 1.79						33.97 32.62	
Non-paroxysmal Mixed	Kuck KH (2021) Marrouche NF (20 Packer DL CABAt Parkash R (2022)	18) VA subgrou		2.17 2.15 1.10 1.49 1.53	1.09 1.34 0.67 0.92	4.32 3.44 1.79 2.41	0.1 0.2	2 0.5		5	10	33.97 32.62	
Non-paroxysmal Mixed G. The incic	Kuck KH (2021) Marrouche NF (20 Packer DL CABAł Parkash R (2022)	18) VA subgrou		2.17 2.15 1.10 1.49 1.53	1.09 1.34 0.67 0.92	4.32 3.44 1.79 2.41	0.1 0.2				10	33.97 32.62	
Non-paroxysmal Mixed G. The incid Group by	Kuck KH (2021) Marrouche NF (20 Packer DL CABAt Parkash R (2022)	18) VA subgrou	nortali	2.17 2.15 1.10 1.49 1.53	1.09 1.34 0.67 0.92 1.04	4.32 3.44 1.79 2.41 2.23	0.1 0.2		ratio and 95% of		10	33.97 32.62	
Non-paroxysmal Mixed G. The incid Group by	Kuck KH (2021) Marrouche NF (20 Packer DL CABA) Parkash R (2022) Dence of all-C Study name	018) VA subgrou ause r	nortali	2.17 2.15 1.10 1.49 1.53 ty Odds La ratio	1.09 1.34 0.67 0.92 1.04	4.32 3.44 1.79 2.41 2.23 pper limit	0.1 0.2				10	33.97 32.62 33.41 Relative weight	
Non-paroxysmal Mixed G. The incid	Kuck KH (2021) Marrouche NF (20 Packer DL CABA) Parkash R (2022) Stence of all-c Study name Di Biase L (2016	018) VA subgrou ause r	nortali	2.17 2.15 1.10 1.49 1.53 ty Odds Lu ratio 1 2.55	1.09 1.34 0.67 0.92 1.04 wer U limit 1.05	4.32 3.44 1.79 2.41 2.23 pper limit 6.17	0.1 0.2				10	33.97 32.62 33.41 Relative weight 53.95	
Non-paroxysmal Mixed G. The incid Group by AF type	Kuck KH (2021) Marrouche NF (20 Packer DL CABA) Parkash R (2022) Dence of all-C Study name	018) VA subgrou ause r	nortali	2.17 2.15 1.10 1.49 1.53 ty Odds La ratio	1.09 1.34 0.67 0.92 1.04	4.32 3.44 1.79 2.41 2.23 pper limit	0.1 0.2				10	33.97 32.62 33.41 Relative weight	
Non-paroxysmal Mixed G. The incid Group by AF type Non-paroxysmal	Kuck KH (2021) Marrouche NF (20 Packer DL CABA) Parkash R (2022) dence of all-c <u>Study name</u> Di Biase L (2016 Kuck KH (2021) Marrouche NF (2	018) VA subgrou ause r) 018)	nortali	2.17 2.15 1.10 1.49 1.53 ty 2.55 0.94 1.61 2.15	1.09 1.34 0.67 0.92 1.04 bwer U limit 1.05 0.33 0.61 1.25	4.32 3.44 1.79 2.41 2.23 pper limit 6.17 2.66 4.27 3.71	0.1 0.2				10	33.97 32.62 33.41 Relative weight 53.95 46.05 32.94	
Non-paroxysmal Mixed G. The incid Group by AF type	Kuck KH (2021) Marrouche NF (2C Packer DL CABA) Parkash R (2022) Jence of all-c <u>Study name</u> Di Biase L (2016 Kuck KH (2021)	018) VA subgrou ause r) 018) NA subgro	nortali	2.17 2.15 1.10 1.49 1.53 ty Odds Li ratio 2.55 0.94 1.61 2.15 1.57	1.09 1.34 0.67 0.92 1.04 bwer U limit 1.05 0.33 0.61 1.25 0.92	4.32 3.44 1.79 2.41 2.23 pper limit 6.17 2.66 4.27 3.71 2.70	0.1 0.2				10	33.97 32.62 33.41 Relative weight 53.95 46.05 32.94 33.39	
Non-paroxysmal Mixed G. The incid Group by AF type Non-paroxysmal	Kuck KH (2021) Marrouche NF (2C Packer DL CABAI Parkash R (2022) dence of all-c <u>Study name</u> Di Biase L (2016 Kuck KH (2021) Marrouche NF (2 Packer DL CABA	018) VA subgrou ause r) 018) NA subgro	nortali	2.17 2.15 1.10 1.49 1.53 ty Odds Li ratio 2.55 0.94 1.61 2.15 1.57	1.09 1.34 0.67 0.92 1.04 bwer U limit 1.05 0.33 0.61 1.25	4.32 3.44 1.79 2.41 2.23 pper limit 6.17 2.66 4.27 3.71	0.1 0.2				10	33.97 32.62 33.41 Relative weight 53.95 46.05 32.94	

Forest plots comparing the changes of LVEF, 6-min walk distance, HF questionnaire score, BNP level, odds ratio for AF recurrence, odds ratio for HF hospitalization, and odds ratio for all-cause mortality of medical treatment versus catheter ablation in patients stratified by different AF types (nonparoxysmal and mixed AF). (A) Change in LVEF in eight studies (nonparoxysmal AF in five, mixed AF in three). (B) 6-min walk distance in six studies (nonparoxysmal AF in five, mixed AF in one). (C) HF questionnaire score in six studies (nonparoxysmal AF in four, mixed AF in two). (D) BNP level in six studies (nonparoxysmal AF in four, mixed AF in two). (E) AF recurrence rate in five studies (nonparoxysmal AF in two, mixed AF in three). (F) HF hospitalization rate in five studies (nonparoxysmal AF in two, mixed AF in two, mixed AF in two, mixed AF in three). (G) All-cause mortality rate in five studies (nonparoxysmal AF in two, mixed AF in two, mixed AF in two, mixed AF in three). (C) AF in three

improvement in HF questionnaire scores in favor of catheter ablation vs. medical treatment was observed in the population with nonparoxysmal AF (mean difference, 0.42; 95% CI, 0.16-0.68) and mixed AF (mean difference, 1.70; 95% CI, 0.68-2.72) (Figure 4C). A significant difference in the change in the BNP level in favor of catheter ablation vs. medical treatment was observed in the population with nonparoxysmal AF (mean difference, 2.96 pg/ml; 95% CI, 0.68-5.24 pg/ml) but not in the population with mixed AF (Figure 4D). The risk of recurrence of AF was significantly lower by catheter ablation compared with medical treatment in the population with mixed AF (OR, 8.25; 95% CI, 1.74-39.19) but not in the population with nonparoxysmal AF (Figure 4E). The overall OR values of HF hospitalization in favor of catheter ablation vs. medical treatment were 2.17 (95% CI, 1.09-4.32) in the population with nonparoxysmal AF and 1.53 (95% CI, 1.04-2.23) in the population with mixed AF (Figure 4F). The incidence of allcause mortality was significantly lower by catheter ablation compared with medical treatment in the population with mixed AF (OR, 1.65; 95% CI, 1.21-2.25) but not in the population with nonparoxysmal AF (Figure 4G).

Discussion

In the whole study population of this meta-analysis, improved LVEF, improved 6-min walk distance, better HF questionnaire score, significantly decreased BNP level, less AF recurrence, less HF hospitalization, and lower all-cause mortality were observed after catheter ablation vs. medical treatment. When the study population was stratified by LVEF, improved LVEF, improved 6-min walk distance, less AF recurrence, and lower all-cause mortality in favor of catheter ablation vs. medical treatment were observed in the population with LVEF ≤50% but not in the population with LVEF ≤35%; however, less HF hospitalization was observed both in the population with LVEF ≤50% and LVEF ≤35%. When the study population was stratified by HF NYHA ≥II, improved LVEF, improved 6-min walk distance, and better HF questionnaire score in favor of catheter ablation vs. medical treatment were observed in the population with HF NYHA ≥II. When the study population was stratified by AF types, improved LVEF, improved 6-min walk distance, better HF questionnaire score, and less HF hospitalization in favor of catheter ablation vs. medical treatment were observed both in the population with nonparoxysmal AF and mixed AF; however, less AF recurrence and lower all-cause mortality in favor of catheter ablation vs. medical treatment were observed only in the population with mixed AF.

Population stratified by different LVEF criteria

The criteria for HF in the enrolled studies differed in LVEF cutoff values, ranging from LVEF $\leq 35\%$ (5, 6, 9, 11) to $\leq 40\%$ (8), $\leq 45\%$ (10), and $\leq 50\%$ (7) or differed in only enrolling patients with a history of HF with NYHA functional

classification \geq II without mention LVEF (12, 13). According to our meta-analysis, improved LVEF, improved 6-min walk distance, less AF recurrence, and lower all-cause mortality in favor of catheter ablation vs. medical treatment were observed in the population with LVEF of 36%–50% and less HF hospitalization was observed both in the population with LVEF \leq 50%, and LVEF \leq 35%.

Population stratified by different AF types

In patients with HF and reduced LVEF, a high prevalence of persistent AF exists and is closely related to underlying heart disease severity and HF functional classes (15). In the enrolled studies of this meta-analysis, the prevalence of nonparoxysmal AF was 68%-100%. Previous meta-analyses comparing catheter ablation vs. medical treatment in terms of clinical outcomes in patients with AF and HF did not specifically stratify the study subjects by different AF types (16, 17). However, the long-term efficacy of catheter ablation vs. medical treatment for different AF types on clinical outcomes may differ and may require more than one catheter ablation procedure for different AF types (18). In this meta-analysis, improved LVEF, improved 6-min walk distance, better HF questionnaire score, and less HF hospitalization in favor of catheter ablation vs. medical treatment were observed both in the population with nonparoxysmal AF and mixed AF; however, AF recurrence and all-cause mortality in favor of catheter ablation vs. medical treatment were only observed in the population with mixed AF but not in the population with nonparoxysmal AF. Nonparoxysmal AF may contribute to more atrial and ventricular structural remodeling and atrial fibrosis, reducing the benefit of catheter ablation for AF, especially in HF patients. Therefore, catheter ablation could achieve more clinical benefits in patients with mixed AF than in patients with nonparoxysmal AF.

Limitations

This study had several limitations. First, the enrollment criteria for HF differed among the nine enrolled studies, and high heterogeneity was found in the analyses of the whole population. Therefore, we performed subgroup analyses, and patients were stratified by different LVEFs, HF history of NYHA \geq II, and AF types. Second, the use of HF biomarkers differed among six studies, three (6, 7, 10) used serum BNP and the other three (5, 11, 13) used N-terminal proBNP. Third, although nine studies were included, over one-third of the 2,074 participants enrolled in this meta-analysis were derived from the HF subgroup of the CABANA study, which contributes a large number of patients with LVEF >50% (12). Fourth, the baseline characteristics of all participants in the enrolled studies were not completely available. Fifth, the enrolled studies had different follow-up periods, while HF hospitalization and all-cause mortality might need longer follow-up periods to show a significant difference between catheter ablation and medical treatment.

Conclusion

This meta-analysis showed improved LVEF, improved 6-min walk distance, less AF recurrence, and lower all-cause mortality in favor of catheter ablation vs. medical treatment in AF patients with HF and LVEF of 36%–50%, and less HF hospitalization was observed both in AF patients with HF and LVEF \leq 50%, and LVEF \leq 35%. Compared with medical treatment, catheter ablation improved LVEF, improved 6-min walk distance, and had better HF questionnaire score and less HF hospitalization in patients with nonparoxysmal AF and mixed AF; however, AF recurrence and all-cause mortality in favor of catheter ablation were observed only in HF patients with mixed AF.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Author contributions

W-CL and P-JW reviewed the articles and wrote the manuscript. Y-NF and H-CC prepared figures. M-CC did the final revision. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. *Circulation.* (2009) 119(18):2516–25. doi: 10. 1161/CIRCULATIONAHA.108.821306

2. Heck PM, Lee JM, Kistler PM. Atrial fibrillation in heart failure in the older population. *Heart Fail Clin.* (2013) 9(4):451–9, viii–ix. doi: 10.1016/j.hfc.2013.07.007

3. Batul SA, Gopinathannair R. Atrial fibrillation in heart failure: a therapeutic challenge of our times. *Korean Circ J.* (2017) 47(5):644–62. doi: 10.4070/kcj.2017.0040

4. Gopinathannair R, Chen LY, Chung MK, Cornwell WK, Furie KL, Lakkireddy DR, et al. Managing atrial fibrillation in patients with heart failure and reduced ejection fraction: a scientific statement from the American heart association. *Circ Arrhythm Electrophysiol.* (2021) 14(6):HAE00000000000078. doi: 10.1161/HAE. 000000000000078

5. MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. *Heart.* (2011) 97(9):740–7. doi: 10.1136/hrt.2010.207340

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2023. 1165011/full#supplementary-material.

SUPPLEMENTARY FIGURE 1

Flowchart of the study selection strategy and inclusion and exclusion criteria for this meta-analysis. AF, atrial fibrillation; HF, heart failure

SUPPLEMENTARY FIGURE 2

Funnel plot showing non-significant publication bias using Egger's test (t, 0.309; df, 6; p = 0.767).

SUPPLEMENTARY FIGURE 3

Funnel plot showing non-significant publication bias using Egger's test (n t, 0.782; df, 4; p = 0.478).

SUPPLEMENTARY FIGURE 4

Funnel plot showing non-significant publication bias using Egger's test (t, 0.028; df, 4; p = 0.979).

SUPPLEMENTARY FIGURE 5

Funnel plot showing non-significant publication bias using Egger's test (t, 0.392; df, 4; p = 0.715).

SUPPLEMENTARY FIGURE 6

Funnel plot showing non-significant publication bias using Egger's test (t, 0.382; df, 3; p = 0.728).

SUPPLEMENTARY FIGURE 7

Funnel plot showing non-significant publication bias using Egger's test (t, 0.180; df, 3; p = 0.869).

SUPPLEMENTARY FIGURE 8

Funnel plot showing non-significant publication bias using Egger's test (t, 0.215; df, 3; p = 0.844).

6. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. *J Am Coll Cardiol.* (2013) 61 (18):1894–903. doi: 10.1016/j.jacc.2013.01.069

7. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). *Circ Arrhythm Electrophysiol.* (2014) 7(1):31-8. doi: 10.1161/CIRCEP.113.000806

8. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. *Circulation.* (2016) 133(17):1637–44. doi: 10.1161/ CIRCULATIONAHA.115.019406

9. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med.* (2018) 378 (5):417–27. doi: 10.1056/NEJMoa1707855

10. Prabhu S, Costello BT, Taylor AJ, Gutman SJ, Voskoboinik A, McLellan AJA, et al. Regression of diffuse ventricular fibrosis following restoration of sinus rhythm with catheter ablation in patients with atrial fibrillation and systolic dysfunction: a substudy of the CAMERA MRI trial. *JACC Clin Electrophysiol.* (2018) 4 (8):999–1007. doi: 10.1016/j.jacep.2018.04.013

11. Kuck KH, Merkely B, Zahn R, Arentz T, Seidl K, Schlüter M, et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. *Circ Arrhythm Electrophysiol.* (2019) 12(12):e007731. doi: 10.1161/CIRCEP.119.007731

 Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. *Circulation*. (2021) 143(14):1377–90. doi: 10.1161/ CIRCULATIONAHA.120.050991

13. Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A, et al. Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial. *Circulation*. (2022) 145(23):1693–1704. doi: 10.1161/CIRCULATIONAHA.121.057095

14. Weinmann K, Aktolga D, Pott A, Bothner C, Rattka M, Stephan T, et al. Impact of re-definition of paroxysmal and persistent atrial fibrillation in the 2012 and 2016

European society of cardiology atrial fibrillation guidelines on outcomes after pulmonary vein isolation. *J Interv Card Electrophysiol.* (2021) 60(1):115–23. doi: 10. 1007/s10840-020-00710-4

15. Schönbauer R, Duca F, Kammerlander AA, Aschauer S, Binder C, Zotter-Tufaro C, et al. Persistent atrial fibrillation in heart failure with preserved ejection fraction: prognostic relevance and association with clinical, imaging and invasive haemodynamic parameters. *Eur J Clin Invest.* (2020) 50(2):e13184. doi: 10.1111/eci.13184

16. Chen S, Pürerfellner H, Meyer C, Acou WJ, Schratter A, Ling Z, et al. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. *Eur Heart J.* (2020) 41(30):2863–73. doi: 10.1093/eurheartj/ehz443

17. Pan KL, Wu YL, Lee M, Ovbiagele B. Catheter ablation compared with medical therapy for atrial fibrillation with heart failure: a systematic review and meta-analysis of randomized controlled trials. *Int J Med Sci.* (2021) 18(6):1325–31. doi: 10.7150/ijms. 52257

18. Mujović N, Marinković M, Lenarczyk R, Tilz R, Potpara TS. Catheter ablation of atrial fibrillation: an overview for clinicians. *Adv Ther.* (2017) 34(8):1897–917. doi: 10. 1007/s12325-017-0590-z